While most fund managers participate in the ASX as investors in other companies, some run their own listed investment companies – and three made this fortnight’s list of director trades over $100,000.

One came from Regal Funds Managements’ Regal Investment Fund (ASX:RF1). It first listed in 2019 and returned to investors for more capital two years on.

Chipping in $202,136 in the rights issue was Michael O’Brien on October 20. The form was lodged with the ASX one day late which the company said was an “administrative oversight”.

The second was Wilson Asset Management boss Geoffrey Wilson who bought $416,832 in stock as part of a dividend reinvestment plan for WAM Leaders (ASX:WLE).

This $1.5 billion company is focused on ASX large caps – including but not limited to the banks and big miners – and has returned 28% in the past 12 months.

Rounding out the list was David Butel from London City Equities (ASX:LCE) who chipped in $161,397 – again as part of a dividend reinvestment plan.


Company buyers

The two biggest buys came from the same director – Raphael Geminder of Pact Group (ASX:PGH). He bought $6 million in shares on October 20 and another $5.1 million on October 26 – both on market.

WA gold and copper explorer AIC Mines (ASX:A1M) re-entered the bourse on Friday after a few months suspended. Aaron Colleran and Josef El-Raghy chipped in as part of its recapitalisation process buying $1.25 million and $5 million respectively.

The biggest company with a purchase of shares was Woolworths (ASX:WOW) – Phillip Chronican bought 7,000 shares on market which cost $271,198.

Christopher Richards from Apiam Animal Health (ASX:AHX) bought $377,171 in a dividend reinvestment plan and Uwe Boettcher from XTek (ASX:XTE) bought $329,284 in a rights issue.



This week Ramelius Resources (ASX:RMS) completed its takeover of Apollo Consolidated (ASX:AOP).

Apollo owns the 1.1Moz Lake Rebecca gold project around 100km east of Kalgoorlie.

Although it is is yet to declare an ore reserve, with 815,000oz in the indicated resource category, Ramelius boss Mark Zeptner thinks it has potential to produce 100,000ozpa for 8-10 years.

Three Apollo directors parted with over $5 million in shares – Robert Gherghetta with $5.15 million, David Castleden with $6.4 million and Roger Steinepreis with nearly $9.3 million.

Paul Perreault, the CEO of blood plasma company CSL (ASX:CSL) sold nearly $4.7 million in shares, in a trade the company said was “for portfolio diversification purposes”.

Still with biotechs, John Cullity from Race Oncology (ASX:RAC) sold ~$710,000 in shares. The company said the deal was to fund the exercise of options and that the shares were directly sold to other existing shareholders.

Genex Power’s (ASX:GNX) Simon Kidston parted with ~$2.5 million in an on-market sale.